Skip to content

The Case Against These Two Hot COVID-19 Vaccine Stocks

The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed. The author, however, believes that it may be best to avoid these two stocks, as “neither has much of a track record in drug development. Nor do they have any history of turning a profit, favorable fundamentals, or other products on the verge of commercialization that might justify the current prices.” What are the two stocks in question? CLICK HERE.